Cellsway

Executive Summary

Cellsway is a UK-based deep-tech liquid biopsy company developing a fully automated microfluidic platform for enrichment, identification, and characterization of Circulating Tumor Cells (CTCs) from a simple blood draw. Founded in 2016 with operational presence also in Turkey, the company aims to set a new gold standard in cancer diagnosis and management by providing clinicians with actionable data for therapy selection and monitoring. The platform integrates microfluidics, imaging, and AI to isolate rare CTCs with high sensitivity and specificity, potentially enabling earlier cancer detection, treatment guidance, and recurrence monitoring. While still in an early stage without disclosed funding or partnerships, Cellsway's technology addresses key limitations of existing liquid biopsy methods, such as low yield and lack of functional characterization. The company's success hinges on clinical validation, regulatory approvals, and commercial adoption in a competitive landscape dominated by players like Guardant Health and Grail. However, its unique focus on CTC enrichment and characterization could carve a niche in precision oncology.

Upcoming Catalysts (preview)

• Q1 2027First Clinical Validation Study Results50% success
• TBDPartnership or Licensing Deal with Diagnostic or Pharma Company30% success
• Q2 2027Series A or B Funding Round Announcement40% success